<DOC>
	<DOCNO>NCT00434044</DOCNO>
	<brief_summary>This study represent sponsor 's first control study etanercept Chinese subject Ankylosing Spondytitis ( AS ) . This trial design assess safety efficacy etanercept compare placebo treatment patient AS .</brief_summary>
	<brief_title>Study Evaluating Etanercept Treatment Subjects With Ankylosing Spondylitis</brief_title>
	<detailed_description>Multicenter , double-blind , randomize , parallel placebo-controlled outpatient study . The study consist 2 part : part A 6-week double-blind treatment period part B 6-week open-label treatment period . During part A study , subject randomly assign 1 2 treatment regimen : 2 etanercept 25 mg placebo weekly , administer subcutaneously ( SC ) . After completion part A , subject receive 2 etanercept 25 mg weekly . The use placebo control part A necessary allow valid comparison provide quantitative assessment effect .</detailed_description>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>1 . Must Chinese ancestry live China . 2 . Diagnosis AS , define Modified New York Criteria Ankylosing Spondylitis . 3 . Active AS time enrollment , define average visual analog scale ( VAS ) value duration intensity morning stiffness 30 two following : VAS patient global assessment 30 ; average VAS nocturnal total pain 30 ; BASFI great equal 30 ( score scale 0 100 ) . 1 . Complete ankylosis ( fusion ) spine . 2 . Previous treatment etanercept , antibody Tumor Necrosis Factor ( TNFa ) , TNFa inhibitor biologic agent . 3 . Use disease modify antirheumatic drug ( DMARDs ) hydroxychloroquine , sulphasalazine , methotrexate within 4 week baseline . Subjects treat hydroxychloroquine , sulphasalazine , methotrexate may continue drug study dos must hold stable 4 week baseline examination duration study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>